Pharma Tech

EASD 2026: CagriSema weight loss holds at submaximal doses in REDEFINE-1 analysis

Sep 30, 2026, 4:40 PM

Read Full Article → EASD 2026: CagriSema weight loss holds at submaximal doses in REDEFINE-1 analysis

Translate article text

Choose a language and wait for the translated text.

Data arrives as drugmakers race to bring successors to popular obesity therapies like semaglutide and tirzepatide to market.